High level of BRD4 promotes non-small cell lung cancer progression
Metrics: PDF 1209 views | HTML 1364 views | ?
Yun-Fei Liao1,2,*, Yong-Bing Wu2,*, Xiang Long2,*, Shu-Qiang Zhu2, Chun Jin1, Jian-Jun Xu2, Jian-Yong Ding1
1Department of Thoracic Surgery, The Affiliated Zhongshan Hospital of Fudan University, Shanghai 200032, P. R. China
2Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, P. R. China
*These authors contributed equally to this work
Jian-Yong Ding, e-mail: firstname.lastname@example.org
Jian-Jun Xu, e-mail: email@example.com
Keywords: non-small cell lung cancer, bromodomain containing protein 4, proliferation, invasion, apoptosis
Received: August 09, 2015 Accepted: January 13, 2016 Published: January 29, 2016
Bromodomain containing protein 4 (BRD4), a member of the bromodomain and extra terminal domain (BET) protein family, has been shown to play important roles in tumor progression. However, its role in non-small cell lung cancer (NSCLC) is still largely unknown. Here, we found that BRD4 expression was significantly upregulated in NSCLC tissues and NSCLC cell lines with higher invasion and metastasis potentials. Suppression of BRD4 expression in NSCLC cell lines impaired cell invasion, inhibited cell proliferation, and accelerated cell apoptosis. Clinically, we observed that the BRD4 level was significantly related to histological type, lymph node metastasis, tumor stage and differentiation. More importantly, high level of BRD4 was closely correlated with the poor prognosis of NSCLC patients. Therefore, our study suggests that BRD4 is one of the major contributors to the invasion-prone phenotype of NSCLC, and a potential therapeutic target of NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.